NBTXR3 First in Class Radioenhancer

Physical Mode of Action that could work across all solid tumors to enhance radiotherapy efficacy.

Only one administration

Fits into existing standard of care:

  • No change in equipment
  • No change in current patient flow
  • No change in protocol
  • One product addressing areas of high unmet medical needs.

    See more

    Recent Press Releases

    Nanobiotix Provides Third Quarter Operational and Financial Update
    Nanobiotix to Present First Survival Data From Priority Head and Neck Cancer Program Among Five Presentations at the 2021 Annual Meeting of the American Society for Radiation Oncology
    Nanobiotix announces Red Journal publication of preclinical data showing radioenhancer NBTXR3 may “reprogram” the tumor microenvironment to overcome anti-PD-1 resistance and evoke abscopal effect



    October 24, 2021

    2021 ASTRO Annual Meeting

    More info
    November 16

    Jefferies London Healthcare Conference

    More info


    “Being part of Nanobiotix is a privilege. The privilege of exploring beyond the edge of science and challenging established and existing limits for the good of humankind. The privilege of being part of an extraordinary adventure to enable people to live a better life. The privilege of expanding life.”

    Anne-Juliette Hermant
    Chief People Officer

    Download our latest
    Corporate Presentation